2013 Clinical Trials Epilepsy Research and Development 
Cannabis Law Report
JULY 27, 2021
and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. –(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. Lindsey Clarke.
The Cannigma
JUNE 15, 2021
Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.
Green Relief
MAY 13, 2018
Preclinical research and anecdotal accounts indicate that CBD is highly active against brain ischemia, modulating many of the molecular hallmarks of TBI pathology. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. The patent.
Cannabis Law Report
NOVEMBER 24, 2021
Published by The Journal of Cannabis Research. At the same time, the outlook on cannabis research data is largely positive. Primary sources most frequently used in these reports are peer-reviewed journals or government reports, voices from medical associations or foundations, as well as government and university researchers.
SMPL
MAY 26, 2020
For years, he’d been determined to connect the nascent CBD research he heard about at symposiums abroad with the medical marijuana movement in California. This makes further research very difficult to do, and causes sick people in many states to be treated as criminals. San Francisco weekly. We were in communication for many years.”.
Cannabis Law Report
JANUARY 20, 2022
Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.
Expert insights. Personalized for you.
105 
Let's personalize your content